Cefazolin Dosing in Children Undergoing Cardiac Surgery With Cardiopulmonary Bypass
NCT ID: NCT02749981
Last Updated: 2023-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
56 participants
OBSERVATIONAL
2012-12-31
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Modified Ultrafiltration on Vancomycin Levels During Cardiopulmonary Bypass in Cardiac Surgery
NCT02051595
Vancomycin and Cefoxitin During Pediatric Cardiopulmonary Bypass
NCT02839486
Pharmacokinetics of Cefuroxime in Cardiac Surgery With Cardiopulmonary Bypass
NCT01228825
Bayesian Networks in Pediatric Cardiac Surgery
NCT05537168
Does Modified Ultrafiltration Improves Inflammatory Response and Cardiopulmonary Function After CABG Procedures?
NCT01140113
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cefazolin
patients receiving cefazolin as part of routine clinical care
blood and tissue sampling
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood and tissue sampling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* minimum weight 1.8 kg
* intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)
Exclusion Criteria
* absence of parental/patient consent
* known hypersensitivity to cefazolin
0 Days
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Ghent
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Katrien Francois, MD
Role: PRINCIPAL_INVESTIGATOR
Ghent University Hospital, Department of Cardiac Surgery
References
Explore related publications, articles, or registry entries linked to this study.
De Cock PA, Mulla H, Desmet S, De Somer F, McWhinney BC, Ungerer JP, Moerman A, Commeyne S, Vande Walle J, Francois K, Van Hasselt JG, De Paepe P. Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass to optimize dosing regimens for children undergoing cardiac surgery. J Antimicrob Chemother. 2017 Mar 1;72(3):791-800. doi: 10.1093/jac/dkw496.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012/631-632-633
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.